Five new pedigrees with inherited RUNX1 mutations causing familial platelet disorder with propensity to myeloid malignancy

Blood
Carolyn J OwenJude Fitzgibbon

Abstract

Familial platelet disorder with propensity to myeloid malignancy (FPD/AML) is an autosomal dominant syndrome characterized by platelet abnormalities and a predisposition to myelodysplasia (MDS) and/or acute myeloid leukemia (AML). The disorder, caused by inherited mutations in RUNX1, is uncommon with only 14 pedigrees reported. We screened 10 families with a history of more than one first degree relative with MDS/AML for inherited mutations in RUNX1. Germ- line RUNX1 mutations were identified in 5 pedigrees with a 3:2 predominance of N-terminal mutations. Several affected members had normal platelet counts or platelet function, features not previously reported in FPD/AML. The median incidence of MDS/AML among carriers of RUNX1 mutation was 35%. Individual treatments varied but included hematopoietic stem cell transplantation from siblings before recognition of the inherited leukemogenic mutation. Transplantation was associated with a high incidence of complications including early relapse, failure of engraftment, and posttransplantation lymphoproliferative disorder. Given the small size of modern families and the clinical heterogeneity of this syndrome, the diagnosis of FPD/AML could be easily overlooked and may be more prevale...Continue Reading

References

Mar 14, 2000·Bone Marrow Transplantation·H T GreinixR Knobler
Jan 17, 2002·Leukemia Research·Chava PerryHermona Soreq
Mar 29, 2002·Genes, Chromosomes & Cancer·Stephen E LangabeerDavid C Linch
Dec 3, 2004·The New England Journal of Medicine·Matthew L SmithJude Fitzgibbon
May 5, 2005·Proceedings of the National Academy of Sciences of the United States of America·Diana VradiiGary S Stein
Jan 5, 2008·British Journal of Haematology·Carolyn OwenJude Fitzgibbon

❮ Previous
Next ❯

Citations

Jun 16, 2010·International Journal of Hematology·Nahoko NishimotoMineo Kurokawa
Apr 25, 2013·International Journal of Hematology·Motoshi IchikawaMineo Kurokawa
May 28, 2009·Molecular and Cellular Biology·Hui HuangAlan B Cantor
Dec 14, 2011·Hematology·Michele P Lambert
May 25, 2011·Haematologica·Elena Liew, Carolyn Owen
Oct 15, 2014·Seminars in Hematology·Lucy A Godley
Sep 1, 2011·Leukemia & Lymphoma·Brigitte SchlegelbergerMichael Heuser
Jan 31, 2016·European Journal of Medical Genetics·Marjolijn C J JongmansNicoline Hoogerbrugge
Oct 20, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Jane E ChurpekLucy A Godley
Jul 14, 2010·Seminars in Hematology·Amy E Geddis
Apr 3, 2010·Hematology/oncology Clinics of North America·Rafael Bejar, Benjamin L Ebert
Dec 17, 2011·Cancer Science·Remond J A FijnemanRobert T Cormier
May 11, 2012·British Journal of Haematology·Olfat IsmaelSeiji Kojima
Mar 21, 2013·Journal of Thrombosis and Haemostasis : JTH·C L BalduiniM Seri
Mar 17, 2010·Genes, Chromosomes & Cancer·Christa Fonatsch
Sep 5, 2015·Blood·Courtney D DiNardo
Feb 25, 2015·British Journal of Haematology·Matthew CollinVenetia Bigley
Feb 11, 2015·Best Practice & Research. Clinical Haematology·Daria V Babushok, Monica Bessler
Jul 15, 2015·Current Opinion in Hematology·Michele P Lambert

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.